Evidence map›Paper›PMID 39421163›Full record

ArticleEcancermedicalscience2024

Report of Henoch-Schönlein purpura associated with trastuzumab emtansine.

Santiago Leandro Escobar-Dávila, Giovanna Patricia Rivas-Tafurt, Luis Álvaro Melo-Burbano, Luis Miguel Osorio-Toro, Edith Norela Benítez-Escobar, Duván Arley Galindes-Casanova, Jorge Hernán Izquierdo-Loaiza, Rodrigo Andrés Cárdenas-Perilla, Carlos Orozco-de la Hoz

Abstract readCase Reports
In one paragraph

Article in Ecancermedicalscience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Santiago Leandro Escobar-DávilaFacultad de Salud, Especialización en Medicina Interna, Universidad Santiago de Cali, Cali, Colombia.
Giovanna Patricia Rivas-TafurtFacultad de Salud, Especialización en Medicina Interna, Universidad Santiago de Cali, Cali, Colombia.
Luis Álvaro Melo-BurbanoFacultad de Salud, Especialización en Medicina Interna, Universidad Santiago de Cali, Cali, Colombia.
Luis Miguel Osorio-ToroFacultad de Salud, Especialización en Medicina Interna, Universidad Santiago de Cali, Cali, Colombia.
Edith Norela Benítez-EscobarFacultad de Salud, Especialización en Medicina Interna, Universidad Santiago de Cali, Cali, Colombia.
Duván Arley Galindes-CasanovaFacultad de Salud, Especialización en Medicina Interna, Universidad Santiago de Cali, Cali, Colombia.
Jorge Hernán Izquierdo-LoaizaFacultad de Salud, Especialización en Medicina Interna, Universidad Santiago de Cali, Cali, Colombia.
Rodrigo Andrés Cárdenas-PerillaMédico Nuclear, Clínica de Occidente, Cali 760046, Colombia.
Carlos Orozco-de la HozNefropatólogo, Biomolecular, Bogotá, Colombia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vasculitides are a set of pathologies that can affect one or several organs, in the short and long term. They are associated with various etiologies, among which paraneoplastic syndromes and medications stand out. Although everyday cancer therapies are more directed against a therapeutic target, their use can cause a wide spectrum of complications. Some treatments against human epidermal growth factor 2 (HER2) have been associated with cutaneous and pulmonary vasculitis. We present the first case of Henoch-Schönlein purpura associated with the use of T-DM1 in a patient with HER2 breast cancer.

Indexed as

Henoch-Schönlein purpuraparaneoplastic syndromevasculitis

Identifiers

PMID39421163
PMCPMC11484666

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.